Company Encyclopedia
View More
name
Weigao Blood Purification
603014.SH
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers, dialysis machines, hemodialysis machines, A.V. fistula needle sets, extracorporeal blood circuits, bloodlines, and plasma separators; peritoneal dialysis (PD) solutions; and PD consumables, such as bag free set, catheter joints, and transfer tube sets.
893.67 B
603014.SHMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking0/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.90%C
    • Profit Margin12.55%B
    • Gross Margin40.57%B
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY0.00%C
    • Total Assets YoY22.22%A
    • Net Assets YoY27.23%A
  • Cash ScoreC
    • Cash Flow Margin797.00%B
    • OCF YoY0.00%C
  • Operating ScoreC
    • Turnover0.46C
  • Debt ScoreA
    • Gearing Ratio16.25%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. Stock resumes trading

    Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through the issuance of shares, with the stock resuming trading on November 3, 2025. This transaction will integrate technology and product layout, expand into the pharmaceutical packaging materials field, and enhance the technical reserves and sales channels of the biopharmaceutical filter business through synergies

    Zhitong·
    SH
    603014
    -0.51%
    Zhitong·
    SH
    603014
    -0.51%

    WEIGAO GROUP is potentially selling over 94% of Weigao Purui to exchange for Weigao Blood Purification A shares

    On October 17th, WEIGAO GROUP signed a non-binding letter of intent, planning to acquire its 94.0706% stake in Weigao Blood Purification, which focuses on the research and production of pharmaceutical packaging materials. This move will further expand the company's overall business landscape

    AASTOCKS·
    SH
    603014
    -0.51%
    HK
    01066
    -1.52%
    AASTOCKS·
    SH
    603014
    -0.51%
    HK
    01066
    -1.52%

    Weigao Blood Purification plans to acquire 100% equity of Weigao Purui, and trading will be suspended from October 20

    According to the Zhitong Finance APP, Weigao Blood Purification announced that the company is planning to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. (hereinafter referred to as "Weigao Purui" or "the target company") through the issuance of shares. Upon the company's application, the company's stock will be suspended from trading starting from October 20, 2025 (Monday), and the suspension is expected to last no more than 10 trading days

    Zhitong·
    SH
    603014
    -0.51%
    Zhitong·
    SH
    603014
    -0.51%

    Weigao Blood Purification will implement the distribution of equity for the first half of 2025, distributing over 65.82 million yuan in cash

    Shandong Weigao Blood Purification Products Co., Ltd. announced the implementation of the 2025 semi-annual equity distribution, planning to distribute a cash dividend of RMB 0.15756 per share based on a total share capital of 417,754,066 shares, totaling a cash dividend distribution of RMB 65,821,330.64. The equity registration date is October 23, 2025, and the ex-dividend date and cash dividend payment date is October 24. The announcement specifies the tax deduction situation for different types of shareholders

    Zhitong·
    HK
    22093
    0.00%
    SH
    603014
    -0.51%
    Zhitong·
    HK
    22093
    0.00%
    SH
    603014
    -0.51%

    Weigao Blood: Net profit of 220 million yuan in the first half of 2025, a year-on-year increase of 10.11%

    Weigao Blood announced that in the first half of 2025, operating revenue was 1.765 billion yuan, a year-on-year increase of 8.52%. Net profit was 220 million yuan, a year-on-year increase of 10.11%. The company plans to distribute a cash dividend of 1.6 yuan for every 10 shares to all shareholders, totaling a cash dividend of 65.8231 million yuan, accounting for 29.89% of the net profit attributable to shareholders of the listed company in the consolidated financial statements

    Zhitong·
    SH
    603014
    -0.51%
    Zhitong·
    SH
    603014
    -0.51%
    © 2025 Longbridge｜Disclaimer